Commonly used to reduce bleeding in patients with hematologic malignancies and severe thrombocytopenia, tranexamic acid (TXA) failed to show this protection in a randomized trial in this setting. Instead, an increased risk for catheter thrombosis associated this preventive strategy with an adverse benefit-to-risk ratio.
TXA has been found to be effective in controlling bleeding in surgery, but “clearly patients with low platelet counts and blood cancers have a different kind of